Retrospective cohort study reveals improvements in heart failure symptoms post heart transplantation in light-chain amyloidosis patients, suggesting effective management strategies.
Key Points
Survival outcomes indicate improved prognosis with heart transplantation in light-chain amyloidosis patients.
The cohort showed a median progression-free survival of 21.3 months and overall survival of 116.5 months after heart transplant.
Heart transplant analysis highlighted significance of early hematologic response and supportive care for these patients.
The study suggests consideration of heart transplant for selected patients suffering from advanced cardiac involvement in light-chain amyloidosis.